Skip to main content
Caplight Logo









Bivision Pharma

Bivision Pharma

Private
NanjingHealthcare & Life Scienceshttps://bivisionpharma.com/

Last Round

Series A

Jul 26, 2024

Total Funding Raised

$28.6M

Company Overview

Bivision Pharma is a biotechnology company that develops targeted radiopharmaceuticals for the diagnosis and treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B2C

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

targeted radionuclide therapyTRTradiopharmaceuticalsradiopharmaradioligand therapytheranosticsmetastatic castration-resistant prostate cancermCRPCprostate cancer therapyPSMA targeted therapyLutetium-177Lu-177oncology drug developmentclinical-stage biopharmasolid tumor therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bivision Pharma Comparables

Compare Bivision Pharma with similar companies based on industry and business-model similarity.

Bivision Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Convergent Therapeutics
87%
Full-Life Technologies|Home
86%
Eli Lilly and Company
85%

Bivision Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 26, 2024
VC RoundMay 14, 2024
AngelMay 1, 2022

Bivision Pharma Investors

Notable investors and investment history

Bivision Pharma investors
InvestorRounds
华金大道投资有限公司Series A
Kaitai CapitalAngel
Huajin CapitalSeries A
Gaorong CapitalSeries A, Angel, VC Round
Hongli Innovation InvestmentAngel, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2024

    $14M round led by Huajin Capital and 华金大道投资有限公司

  • May 14, 2024

    Led by Gaorong Capital and Hongli Innovation Investment.

Bivision Pharma Filings

Explore SEC and related filing metadata, where available.

Bivision Pharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Bivision Pharma's valuation, stock price, and market status.

Is Bivision Pharma a public or private company?

Bivision Pharma is a private company.

What is the current stock price of Bivision Pharma?

Bivision Pharma is a private company with no public stock price. No recent secondary market data is available.

How much is Bivision Pharma worth (valuation)?

Valuation information for Bivision Pharma is not publicly available.

Can I buy Bivision Pharma stock?

Bivision Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Bivision Pharma's last funding round?

Bivision Pharma's most recent funding round was Series A on July 26, 2024.

Who are the main investors in Bivision Pharma?

Key investors in Bivision Pharma include 华金大道投资有限公司, Huajin Capital, Gaorong Capital, Hongli Innovation Investment.

Will Bivision Pharma IPO soon?

No public IPO plans have been announced for Bivision Pharma.

How can I track Bivision Pharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Bivision Pharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNanjing
Year Founded2021
Last FundingJul 26, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?